In the last trading session, 2.51 million shares of the Candel Therapeutics Inc (NASDAQ:CADL) were traded, and its beta was -1.15. Most recently the company’s share price was $8.06, and it changed around -$0.19 or -2.30% from the last close, which brings the market valuation of the company to $380.72M. CADL currently trades at a discount to its 52-week high of $14.60, offering almost -81.14% off that amount. The share price’s 52-week low was $1.40, which indicates that the current value has risen by an impressive 82.63% since then. We note from Candel Therapeutics Inc’s average daily trading volume that its 10-day average is 0.96 million shares, with the 3-month average coming to 1.29 million.
Candel Therapeutics Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.00. If we narrow it down even further, the data shows that 0 out of 4 analysts rate the stock as a Sell; another 1 rate it as Overweight. Among the rest, 0 recommended CADL as a Hold, whereas 3 deemed it a Buy, and 0 rated it as Underweight. Candel Therapeutics Inc is expected to report earnings per share of -0.24 for the current quarter.
Candel Therapeutics Inc (NASDAQ:CADL) trade information
Instantly CADL has showed a red trend with a performance of -2.30% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 9.08 on recent trading dayincreased the stock’s daily price by 11.23%. The company’s shares are currently down -7.14% year-to-date, but still down -7.89% over the last five days. On the other hand, Candel Therapeutics Inc (NASDAQ:CADL) is -33.99% down in the 30-day period. We can see from the shorts that 3.34 million shares have been sold at a short interest cover period of 2.54 day(s).
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -43.86%. Candel Therapeutics Inc earnings are expected to increase by 29.34% in 2025, but the outlook is positive 24.13% per year for the next five years.
CADL Dividends
Candel Therapeutics Inc’s next quarterly earnings report is expected to be released on 2025-Mar-12.
Candel Therapeutics Inc (NASDAQ:CADL)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 18.54% of Candel Therapeutics Inc shares, and 44.13% of them are in the hands of institutional investors. The stock currently has a share float of 54.18%. Candel Therapeutics Inc stock is held by 97.0 institutions, with NORTHPOND VENTURES, LLC being the largest institutional investor. By 2024-06-30, it held 6.477% of the shares, which is about 1.94 million shares worth $12.0 million.
BLACKROCK INC., with 2.819% or 0.82 million shares worth $5.1 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
Biotechnology Portfolio and Vanguard Total Stock Market Index Fund were the top two Mutual Funds as of Jan 31, 2025 . The former held 5.54 shares worth $44.69 million, making up 11.74% of all outstanding shares. On the other hand, Vanguard Total Stock Market Index Fund held roughly 866.65 shares worth around $6.99 million, which represents about 1.83% of the total shares outstanding.
